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Background: The Burkholderia cenocepacia 
lipid A is hypoacylated. 
Results: Aminoarabinose residues in lipid A 
contribute to Burkholderia lipid A binding to the 
TLR4/MD-2 complex. 
Conclusion: A novel mode of Burkholderia 
lipopolysaccharide-TLR4/MD-2 interactions 
promotes inflammation. 
Significance: Modifications of the lipid A 
structure enhance pro-inflammatory responses of 
hypoacylated lipopolysaccharide.
 http://www.jbc.org/cgi/doi/10.1074/jbc.M115.649087The latest version is at 
JBC Papers in Press. Published on July 9, 2015 as Manuscript M115.649087
 Copyright 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
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ABSTRACT
 Lung infection by Burkholderia species, in 
particular B. cenocepacia, accelerates tissue 
damage and increase post-lung transplant 
mortality in cystic fibrosis patients. Host-
microbes interplay largely depends on 
interactions between pathogen specific 
molecules and innate immune receptors such 
as the Toll-like receptor 4 (TLR4), which 
recognizes the lipid A moiety of the bacterial 
lipopolysaccharide (LPS). The human 
TLR4/MD-2 LPS receptor complex is strongly 
activated by hexa-acylated lipid A and poorly 
activated by underacylated lipid A. Here, we 
report that B. cenocepacia LPS strongly 
activates human TLR4/MD-2 despite its lipid 
A having only five acyl chains. Further, we 
show that aminoarabinose residues in lipid A 
contribute to TLR4-lipid A interactions, and 
experiments in a mouse model of LPS-induced 
endotoxic shock confirmed the pro-
inflammatory potential of B. cenocepacia 
penta-acylated lipid A. Molecular modeling, 
combined with mutagenesis of TLR4-MD2 
interactive surfaces, suggests that longer acyl 
chains and the aminoarabinose residues in the 
B. cenocepacia lipid A allow exposure of the 
fifth acyl chain on the surface of MD-2 
enabling interactions with TLR4 and its 
dimerization. Our results provide a molecular 
model for activation of the human TLR4/MD-
2 complex by penta-acylated lipid A, 
explaining the ability of hypoacylated B. 
cenocepacia LPS to promote pro-
inflammatory responses associated to the 
severe pathogenicity of this opportunistic 
bacterium. 
 
A central theme in innate immunity involves 
recognition of conserved microbial molecules 
(pathogen-associated molecular patterns) by 
surface receptors expressed on phagocytic cells 
(1,2). Pathogen recognition triggers cell 
signaling cascades leading to activation of 
transcription factors such as nuclear factor-κB 
(NF-κB) and interferon regulatory factors (IRFs), 
which in turn stimulate production of 
inflammatory cytokines (e.g. TNF-α, IL-1β, and 
type I interferons) (3). Lipopolysaccharide 
(LPS), the major component of the Gram-
negative bacterial outer membrane, elicits potent 
innate immune responses through interactions 
with a receptor complex composed of Toll-like 
receptor 4 (TLR4) and the myeloid 
differentiation factor 2 (MD-2) (4). Depending 
on the amount and chemical nature of LPS 
released from the pathogen, TLR4/MD-2 
recognition stimulates a protective immune 
response or leads to uncontrolled inflammation 
associated with high mortality (5,6). LPS is a 
complex glycolipid consisting of three distinct 
domains (Fig. 1) (7): lipid A, core 
oligosaccharide, and in many bacteria, a 
repeating polysaccharide moiety known as the 
O-antigen (8-10). Lipid A, composed of an 
acylated glucosamine disaccharide backbone, is 
the LPS moiety recognized by the TLR4/MD-2 
receptor complex. Lipid A bioactivity depends 
on its chemical structure. The number and 
distribution of acyl chains, and the presence of 
the phosphate groups in the di-glucosamine 
backbone determine the agonistic and 
antagonistic activities of lipid A (11-19). Most 
enteric bacteria, such as Escherichia coli, 
produce hexa-acylated bis-phosphorylated lipid 
A, which has the highest cytokine-inducing 
capacity in mammals. In contrast, tetra-acylated 
lipid A (as lipid IVA) and most of penta-acylated 
lipid A forms lack activity on human cells 
(19,20).  
Lipid A interacts with a hydrophobic pocket 
formed by two anti-parallel β-sheets of MD-2 
mediating the dimerization and activation of the 
TLR4/MD-2 complex (19,21). The MD-2 
hydrophobic pocket can accommodate up to five 
acyl chains. For agonistic hexa-acylated E. coli 
lipid A, five acyl chains are buried within the 
pocket while the sixth chain lies on a channel of 
the MD-2 surface, building a hydrophobic region 
and the dimerization interface required for 
interaction with the TLR4 partner  (referred to 
here as TLR4*). This arrangement enables 
hydrophobic interactions bridging the 
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TLR4/MD-2/LPS heterodimer and promoting the 
juxtaposition of the intracellular domains leading 
to activation of signal transduction (18,22). By 
contrast, antagonist lipid IVA binds to human 
MD-2 with all four acyl chains completely 
buried in the hydrophobic pocket precluding 
dimerization and subsequent activation (23). 
Similarly, many penta-acylated lipid As act as an 
antagonist of human TLR4/MD-2 (24-25). In 
contrast, lipid IVA can activate the murine 
TLR4/MD-2 complex (26). 
Bacteria regulate the degree of lipid A 
acylation in response to environmental 
conditions. For example, Pseudomonas 
aeruginosa strains possess penta-acylated lipid 
A, but can produce hexa-acylated lipid A during 
infection in cystic fibrosis (CF) patients (27), 
gaining the ability to elicit stronger 
inflammation. Intriguingly, the non-CF pathogen 
Porphyromonas gingivalis produces a high 
heterogeneous LPS lipid A whose penta-acylated 
isoform potently activates the NF-kB pathway in 
human gingival fibroblasts in a similar manner to 
the E. coli LPS (28).  Therefore, the molecular 
mechanisms underlying TLR4 dimerization and 
activation cannot always be predicted based on 
the E. coli lipid A-TLR4/MD2 paradigm. 
Burkholderia cenocepacia is an opportunistic 
Gram-negative bacterium causing serious 
infections in CF patients (29). Understanding 
how B. cenocepacia infection elicits 
inflammation is crucial to find new ways to 
improve treatment of infected CF patients. The 
structure of the B. cenocepacia LPS (LPSBC) was 
previously described (30). The lipid A moiety of 
LPSBC consists of a mixture of penta-acylated 
and tetra-acylated, bis-phosphorylated di-
glucosamine backbone with two 4-amino-4-
deoxy-L-arabinose (L-Ara4N) residues linked by 
phosphodiester linkages (Fig. 1) (30). The acyl 
chains are made of 3-(R)-hydroxyhexadecanoic 
acid C16:0 (3-OH), 3-(R)-hydroxytetradecanoic 
acid C14:0 (3-OH) and hydroxytetradecanoic 
acid C14:0 (Fig. 1) (30). The L-Ara4N decoration 
of lipid A is essential for B. cenocepacia 
viability (31) and represents the major 
determinant of resistance to cationic 
antimicrobial peptides (30,31). The structural 
features of LPSBC suggest the molecule would be 
a very poor TLR4/MD-2 complex agonist 
compared to the prototypic enterobacterial LPS. 
In contrast, several studies show that LPSBC, as 
well as biological and synthetic lipid A 
analogues, is highly pro-inflammatory (32-36). 
Therefore, the current model for 
binding/activation of human TLR4/MD-2 
complex cannot explain why LPSBC is pro-
inflammatory. In this work, we investigated the 
molecular basis of the mechanism of LPSBC 
recognition and report for the first time that 
longer acyl chains than those in enterobacterial 
lipid A together with the L-Ara4N residues allow 
B. cenocepacia lipid A (LABC) to fit into the 
binding pocket of MD-2 in a manner that 
promotes TLR4 dimerization, leading to 
activation of inflammatory responses in cellular 
and animal models.  
 
EXPERIMENTAL PROCEDURES 
LPS extraction and purification–LPS was 
prepared from B. cenocepacia strains MH71 and 
MH75 (30). Both strains are isogenic derivatives 
of the K56-2 clinical isolate and contain a 
deletion of the wbiF gene that eliminates O-
antigen production. MH75 has also a deletion 
removing genes involved in UDP-L-Ara4N 
synthesis and therefore cannot produce LPS with 
L-Ara4N residues (LPSBCΔAra). Both MH71 and 
MH75 also carry a suppressor mutation in the 
LPS transport gene lptG that allows for the 
transport of LPS devoid of L-Ara4N to the 
bacterial outer membrane (30). The P. 
aeruginosa RP73 clinical isolate was obtained 
from a chronically infected CF patient and kindly 
provided by Prof. Burkhard Tümmler (Klinische 
Forschergruppe, Medizinische Hochschule 
Hannover, Germany) (37,38). Strains were 
plated on trypticase soy agar (TSA) plates and 
cultured in trypticase soy broth (TSB) at 37 °C. 
For large-scale LPS purification, bacteria were 
treated with hot phenol/water (39). After 
extensive dialysis against distilled water, the 
extracted phases were subjected to enzymatic 
digestions to remove nucleic acids and protein 
contaminants. Water and phenol fractions were 
analyzed by 13.5% SDS-PAGE and silver 
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staining (40). The LPS fraction was exclusively 
found in the water phase.  
Isolation of lipid A–Lipid A was obtained 
by hydrolysis of the LPS with 100 mM sodium 
acetate buffer pH 4.4, (100°C, 3 h). The 
solution was extracted three times with 
CHCl3/MeOH/H2O (100:100:30 v/v/v) and 
centrifuged (4°C, 5000 x g, 15 min). The 
organic phase contained lipid A and the water 
phase contained the core oligosaccharide. The 
former was further purified through several 
washes with distilled water and then 
liophilized. The lipid A and core 
oligosaccharide structures of strains K56-2, 
MH71 and MH75 were characterized 
elsewhere (Fig. 1) (30,41). 
Mice endotoxic studies–Animal studies 
were conducted according to protocols 
approved by San Raffaele Scientific Institute 
(Milan, Italy) Institutional Animal Care and 
Use Committee (IACUC) and adhered strictly 
to the Italian Ministry of Health guidelines for 
the use and care of experimental animals. 
Efforts were made to minimize the number of 
animals used and their suffering. C57BL/6 
mice, 20-22 g male (Charls River) were 
challenged via intraperitoneal (i.p.) injection 
with 300 μg/mouse of LPS from E. coli and P. 
aeruginosa RP73, LPSBC, and LPSBCΔAra. 
Control mice were challeged with sterile saline 
solution. Five hours after treatment, mice were 
sacrificed by CO2 administration, and blood 
collected from heart puncture. The blood clot 
was left at room temperature for 15-30 min. 
The clot was removed by centrifugation at 
2,000 x g for 10 min at 4°C. Sera were 
collected and stored at -20 °C. TNF-α 
concentration in sera was determined by 
ELISA (R&D Systems), according to 
manufacturer instructions using antibody pairs 
and recombinant standards from R&D System. 
HEK293 cell activation and luciferase 
reporter assays–Expression plasmids containing 
sequences of human TLR4, MD-2 and the 
pELAM-1 firefly luciferase plasmid were a gift 
from Dr. C. Kirschning (Technical University of 
Munich, Germany). Expression plasmid 
containing sequence of mouse TLR4 was 
purchased from InvivoGen (CA, USA). 
Expression plasmid for mouse MD-2 was a gift 
from Dr. Y. Nagai (University of Tokyo, Japan). 
The Renilla luciferase phRL-TK plasmid was 
purchased from Promega (WI, USA). 
Recombinant MD-2 genes were cloned into pEF-
BOS with Flag and His tags on the C-terminus. 
Recombinant TLR4 genes were cloned into 
pUNO with a C-terminal HA tag. Transfection 
reagent JetPEI was purchased from Polyplus-
Transfection (France) and was used according to 
the manufacturer’s instructions. The human 
embryonic kidney (HEK) 293 cells were 
provided by Dr. J. Chow (Eisai Research 
Institute, Andover, USA) and grown in DMEM 
supplemented with 10 % FBS. The MD-2 
mutants were made using QuikChange site-
directed mutagenesis kit (Stratagene, USA) 
according to the manufacturer’s instructions. All 
plasmids were sequenced to confirm the 
appropriate mutations. For the NF-κB-luciferase 
reporter assay, HEK293 cells were seeded in 96-
well plates at 3 x 10
4
 cells/well and incubated 
overnight in a humidified atmosphere (5% CO2) 
at 37 °C. The next day, when cells were 60-80% 
confluent, they were co-transfected with the 
plasmids for MD-2 (10 ng), TLR4 (1 ng), NF-
κB-dependent luciferase (50 ng) and constitutive 
Renilla luciferase (10 ng) using JetPEI 
transfection reagent (all amounts are in ng/well). 
Cells were stimulated 6 h after transfection with 
endotoxin preparations. Cells were lysed after 16 
h of stimulation in 1x reporter assay lysis buffer 
(Promega, USA) and analysed for reporter gene 
activities using a dual-luciferase reporter assay 
system. Relative luciferase units (RLU) were 
calculated by normalizing each sample’s 
luciferase activity for constitutive Renilla 
activity measured within the same sample. 
Statistical analysis–Results were expressed as 
mean±S.D from experiments done in triplicate. 
Statistical calculations and tests in vitro and in 
vivo were performed using Student’s t test 
considering P ≤ 0.05 as limit of statistical 
significance and a P value of 0.001 extremely 
significant. 
Molecular modeling: building and geometry 
optimization of LPSBC and LPSBCΔAra–3-D 
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coordinates were built by Maestro (42). 
Molecular mechanics optimization (UFF force 
field), semi-empirical calculations (AM1), and 
DFT (B3LYP/6-31G*) were subsequently 
applied using Gaussian03 (43). Ammonium and 
carboxylic acid groups were considered as 
ionized. Conformational analysis on DS1, DS2 
and DS3 disaccharides was performed with 
Macromodel (44). The parameters were: MM3* 
force field, water solvent constant dielectric, 
dielectric constant of 1.0. The charges from the 
force field were employed, with an extended cut-
off. The best conformers were selected, and from 
them molecular dynamics simulations (MDS) 
with implicit water and MM3* as force field, 
were performed using Schrödinger Maestro 9.3 
Impact 5.8 (42,45) (MM3* force field, dielectric 
constant: 80.0 number of MDS steps 100, time 
step (ps) 0,001). 
The full 3D structures of LABCΔAra, LABC, and 
LPSBC were built with Maestro, using optimized 
disaccharide scaffolds obtained from the 
conformational analysis. FA chains, DS6 and 
amino-arabinoses were optimized separately 
using Gaussian 03 (B3LYP/6-31G*). Starting 
conformation for lipid A optimization was 
obtained from E. coli lipid A from PDB 3fxi. 
Full structure of LPSBC was built by putting 
together core region disaccharides and lipid A 
with five aliphatic chains. Final MDS of the 
geometry was performed with implicit water by 
means of Impact (MM3* force field, dielectric 
constant: 80.0, number of MDS steps 100, time 
step (ps) 0,001). 3D Structures of lipid A 
molecules for validation were extracted from 
their corresponding PDB files (E. coli lipid A 
was obtained from PDB 3fxi, and Re chemotype 
of E. coli lipid A from PDB 3vq2), refined with 
the help of Maestro, and finally submitted to 
MDS with Impact (MM3* force field, and 
implicit water). 
Molecular modeling–For docking studies 
with MD-2 and TLR4 proteins, 3D coordinates 
from MD-2 protein were obtained from PDB 
3fxi (human MD-2) and 3vq2 (murine MD-2), 
and refined and minimized with the Protein 
Preparation Wizard module of Maestro, using 
amber force field (46). The TLR4 structure was 
obtained from PDB 3fxi, and treated following 
the same procedure after removing water 
molecules and any other non-standard residue. 
Two different docking methodologies were 
used for docking studies of LABCΔAra and LABC 
on MD-2: AutoDock and AutoDock Vina. While 
AutoDock is a widely used semi-empirical 
docking method (47), the recently released 
AutoDock Vina combines empirical and 
knowledge-based scoring functions, with good 
performance and reduced computing time (48). 
Each ligand was docked into human and murine 
MD-2 protein using AutoDock 4.2 (49), and 
separately using AutoDock Vina 1.1.2. (48). For 
human MD-2 (from PDB 3fxi), the Autogrid grid 
point spacing was set at 0.375 Å, center 
coordinates of the grid box were 29.00, -7.00, 
17.875(x, y, z), and number of grid points in xyz 
was 41, 53, 83. For murine MD-2 (from PDB 
3vq2), the Autogrid grid point spacing was set at 
0.375 Å, center coordinates of the grid box were 
-27.50, -15.50, 22.00 (x, y, z), leading to with 75 
x 40 x 60 (x, y, z) grid points. The best result 
from each docking job with LABC was used as 
starting geometry for subsequent docking 
calculations. Different combinations of allowed 
rotatable bonds were also considered for the 
ligands. Docking calculations with AutoDock 
were performed using Genetic Algorithm 
(number of individuals in population 150, 
maximum number of energy evaluations 
2500000-5000000, maximum number of 
generations 27000, number of top individuals to 
survive to next generation 1, rate of gene 
mutation 0.02, rate of crossover 0.8, window size 
10, Alpha parameter of Cauchy distribution 0.0, 
Beta parameter Cauchy distribution 1.0). When 
docking LPSBC, flexible docking was also 
performed considering Asp101, Glu120 and 
Glu122 as flexible residues. Docking 
calculations with AutoDock Vina were also 
performed. Coordinates and dimensions of grid 
boxes, starting geometries and general 
methodology were the same as for AutoDock. 
When docking LPSBC, flexible docking was also 
performed considering Asp101 as flexible 
residue. 3D structures of the docked complexes 
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were optimized by MDS with Impact (implicit 
water, and AMBER* force field). 
For docking experiments studies of the B. 
cenocepacia LPS core on human TLR4 we used 
AutoDock Vina 1.1.2. Torsional bonds from the 
ligand were allowed to rotate. Ammonium 
groups were considered as ionized. Grid box was 
built on TLR4 from PDB 3fxi with grid center at 
26.00, -22.00, 11.50 (x, y, z), number of grid 
points of 41 x 41 x 43 (x, y, z), and spacing of 
0.375 Å. Final optimization of the 3D structure 
of the docked complex was carried out by MDS 
with Impact (implicit water, and AMBER* force 
field). 
The full complex of human TLR4/MD-2 with 
B. cenocepacia LPS core was built by merging 
docked MD-2/LPS core complex with docked 
LPS inner core/TLR4 using PDB 3fxi as 
template. The resulting structure was optimized 
by MDS with implicit water (AMBER* force 
field). Coupling of two TLR4/MD-2/LPSBC 
complexes was finally performed also using 
PDB 3fxi as template. The full 3D structure of 
the dimer complex was submitted to MDS with 
implicit water and AMBER* force field (charges 
from: force field, cut-off: extended, method: 
PRCG, maximum iterations: 500, converge on: 
gradient, convergence threshold: 0.05). This final 
structure for the TLR4/MD-2/LPSBC complex 
was used to generate the mutant TLR4/MD-
2/LPSBC complex (D294A, R322A, S415A*, and 
S416A*) by changing the corresponding side 
chains to Ala side chain. The resulting structure 
was submitted to MDS with implicit water and 
AMBER* force field. Energy analysis was 
performed by means of the MM-ISMSA 
method (50). 
RESULTS  
LPS and lipid A from B. cenocepacia activate 
the TLR4/MD-2 complex and have pro-
inflammatory activity in vivo–TLR4/MD-2 
activation by LPSBC and LABC was examined 
using the NF-κB reporter luciferase assay in 
transiently transfected HEK293 and HEK293T 
cells co-expressing murine or human MD-2 
(mMD-2, hMD-2) and murine or human TLR4 
(mTLR4, hTLR4). Initial results revealed that 
LPSBC and LABC activate both human and mouse 
TLR4/MD-2 complexes (Figs. 2, 3A and 3B). 
Since LABC possesses longer acyl chains than 
those in E. coli lipid A and constitutively carries 
one or two L-Ara4N residues, to further 
understand the structure-function relationship of 
LPSBC, we utilized LPS from a mutant strain 
lacking the ability to produce L-Ara4N 
(LPSBCΔAra). NF-κB reporter luciferase assays 
demonstrated that at 5 ng/ml, LPSBC and 
LPSBCΔAra induced activation of TLR4/MD-2 
complexes (Fig. 2). Similar results were obtained 
in dose-response experiments with purified LABC 
and LABCΔAra (at 5, 10, and 50 ng/ml) in cells co-
expressing mTLR4/mMD-2 and hTLR4/hMD-2 
(Figs 3A and 3B, respectively), which also 
demonstrated consistent agonistic activity at the 
lowest concentration of 5 ng/ml. However, NF-
B activation by mouse (Fig. 3A) and human 
(Fig. 3B) complexes was significantly lower with 
LABCΔAra, suggesting that the L-Ara4N 
modification of the lipid A plays a role in 
bioactivity of the LPS molecule. 
Comparisons with NF-B activation elicited 
by synthetic E. coli-type hexa-acylated lipid A 
revealed significantly less activation by LPSBC 
and LABCΔAra (all at 50 ng/ml) (Figs. 3A and 3B). 
Lower activation by LPSBC and LPSBCΔAra could 
depend on weaker binding to MD-2 or less 
efficient activation of TLR4. Therefore, we 
examined whether LPSBC and LPSBCΔAra could 
interfere with TLR4 signaling elicited by the E. 
coli LPS by a competition assay in which 
HEK293 cells transfected with hTLR4/hMD-2 
were pre-incubated with LPSBC or LPSBCΔAra for 
1 h and then re-stimulated with E. coli LPS for 4 
h (Fig. 4). Pre-incubation of cells with 10 ng/ml 
of LPSBC followed by stimulation by 1 ng/ml of 
E. coli LPS, revealed weaker NF-kB activation 
than that with E. coli LPS alone (P < 0.05; Fig. 
4). Interestingly, a two-fold reduction in NF-kB 
activation was evident in the case of pre-
incubation with 10 ng/ml of LPSBCΔAra (P < 0.01; 
Fig. 4). Further, a significant difference was 
found in activation by 10 ng/ml of E. coli LPS 
alone compared to that obtained after pre-
incubation of cells with 100 ng/ml of LPSBC and 
LPSBCΔAra (P < 0.01; Fig. 4). In contrast, this 
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inhibitory effect was reduced by increasing the 
concentration of the pre-incubated LPSBC and 
LPSBCΔAra (100 ng/ml) added to the 1 ng/ml of E. 
coli LPS; such effect is probably due to the 
contribution of a weak activation of MD-2/TLR4 
by LPSBC and LPSBCΔAra. Collectively, these 
results suggest that LPSBCΔAra efficiently binds to 
TLR4/MD-2 but is a weaker agonist compared to 
the E. coli LPS and LPSBC.  
The pro-inflammatory activity of LPS from 
B. cenocepacia was assessed using an 
established in vivo model of endotoxic shock. 
C57Bl/6 mice were challenged by intraperitoneal 
injection of LPS from E. coli, P. aeruginosa 
RP73 (a CF strain expressing penta- and tetra-
acylated lipid A (37)), LPSBC and LPSBCΔAra. 
After 5 h of treatment, TNF-α levels in sera were 
measured to evaluate pro-inflammatory and 
endotoxic potential. Compared to the saline 
solution control, penta-acylated LPSBC induced 
robust TNF-α production (LPSBC vs Ctrl P < 
0.01; Fig. 5), while LPSBCΔAra induced three-fold 
less systemic release of TNF-α in sera (LPSBCΔAra 
vs LPSBC P < 0.01, Fig. 5), suggesting a role for 
L-Ara4N residues in the endotoxic LPS response, 
also in agreement with the in vitro results (Fig. 
2). 
Identification of MD-2 amino acid residues 
involved in the interaction with LPSBC–To 
further investigate the molecular recognition of 
LPSBC and LPSBCΔAra by TLR4/MD-2, we 
constructed targeted hMD2 and mMD-2 mutants 
that were co-expressed with hTLR4 or mTLR4 
in transfected HEK293 cells. We focused on 
residues at the dimerization interface of the MD-
2 protein (22,51). In particular, we examined 
valine-82 (Val82), located in the proximity to the 
pocket entrance at a loop between β-strands 5 
and 6. This region contains several conserved, 
solvent-exposed hydrophobic residues that 
contribute to crucial hydrophobic interactions in 
the activated receptor complex (22). Val82 was 
replaced by phenylalanine (V82F) to augment 
the hydrophobic interactions of the MD-2/lipid A 
complex with TLR4. In comparison to HEK293 
cells transfected with parental MD-2, 
hTLR4/hMD-2 V82F led to increased activation 
upon stimulation with LPSBC and LPSBCΔAra, 
while E. coli LPS activation was not 
significantly modified (Fig. 6). This agrees with 
the notion that hexa-acylated lipid A provides 
stronger hydrophobic interactions with TLR4, 
and therefore increased hydrophobicity at 
position 82 augments the activation by penta-
acylated LPS. No significant differences were 
detected between stimulation with LPSBC and 
LABCΔAra on hTLR4/hMD-2 V82F. Hydrophobic 
interactions between mTLR4/mMD-2 and LA 
are expected to be similar to those involving the 
hTLR4/hMD-2 complex since nearly all the 
hydrophobic residues are conserved (51). 
However, the electrostatic interactions that 
contribute to receptor selectivity differ between 
mMD-2 and hMD-2 proteins. Particularly, hMD-
2 has a positively charged lysine at position 122 
near the pocket entrance, whereas mMD-2 has a 
negatively charged glutamic acid (51). 
Moreover, hMD-2 has a positively charged 
lysine at position 125, while mMD-2 has a 
hydrophobic leucine (51). In the complex, lysine 
residues 122 and 125 are close to the 
disaccharide backbone of LA (52) and are 
important for the species-specific differences in 
the recognition of lipid IVA between hMD2 and 
mMD-2. We therefore introduced amino acid 
replacements at positions 122 and 125 in both 
MD-2 homologues to test whether the 
substitutions could affect LA binding and 
influence the selectivity of TLR4 activation by 
the LABC variants. The E122K replacement in 
mMD-2, introducing the equivalent lysine of 
hMD-2, had little or no effect on the activation 
induced by LABC, LABCΔAra or the hexa-acylated 
lipid A. In contrast, this replacement 
significantly decreased activation by lipid IVA (P 
< 0.001; Fig. 7), likely due to removal of the 
repulsive forces towards its bis-phosphorylated 
disaccharide backbone. These repulsive 
interactions have been proposed to be important 
for positioning of lipid IVA in an appropriate 
orientation for TLR4 dimerization (52). Thus, 
the unchanged LABC/LABCΔAra responsiveness 
suggests that the single residue at position 122 of 
the murine MD-2 protein is not critical for 
LABC/LABCΔAra signaling.  
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Stimulation of cells expressing the double 
E122K/L125K mMD-2 replacement (Fig. 7) 
showed substantially increased activity of the 
mutant MD-2 regardless of the LPS variant 
(Hexa-acylated lipid A vs Hexa-acylated lipid A 
P < 0.05, LABC vs LABC P < 0.001, LABCΔAra vs 
LABCΔAra P < 0.001 respectively on 
mTLR4/mMD-2 and mTLR4/mMD-2 E122K 
L125K; Fig. 7), except with lipid IVA whose 
activity was strongly impaired (P < 0.001; Fig. 
7). On the other hand, hMD-2 in combination 
with mTLR4 exhibited significantly stronger 
activation by LPSBCΔAra (P < 0.05; Fig. 7), 
demonstrating that the L-Ara4N affects 
interaction with the TLR4 ectodomain. 
Moreover, the hMD-2 K122E mutant had an 
additive effect in combination with mTLR4 on 
the activation induced by LABCΔAra, showing an 
increment of the NF-B activity (LABCΔAra 
mTLR4/hMD-2 K122E vs LABCΔAra 
hTLR4/hMD-2 P < 0.001; LABCΔAra 
mTLR4/hMD-2 K122E vs LABCΔAra 
mTLR4/hMD-2 P < 0.05; Fig. 7). This probably 
reflects the presence of repulsive forces towards 
the phosphate groups of the lipid A, which might 
facilitate the orientation toward the 
Cys95/Cys105 loop (52,53). 
Together, these experiments using hMD-2 
and mMD-2 mutants support the notion that the 
peculiar structure of the LABC plays a key role in 
its interaction with MD-2, as well as in the 
dimerization process. Our data suggest that the 
L-Ara4N molecules on the di-glucosamine 
backbone influence the binding of lipid A to the 
TLR4/MD-2 complex, although their absence is 
not sufficient to impair signaling.   
Molecular modeling of LPSBC binding to 
TLR4/MD-2–Our previous results suggested that 
different MD-2 binding affinities drive the 
agonist activity of LPS. To provide a model for 
the interactions of LPSBC and LPSBCΔAra, docking 
calculations were undertaken and the two ligands 
were docked into hMD-2 and mMD-2 proteins. 
Validation of the docking protocols was 
performed with AutoDock and AutoDock Vina 
by docking E. coli lipid A into the MD-2 protein 
from their corresponding crystallographic 
structures (PDB codes 3fxi –human and 3vq2 –
murine). Values of root-mean-square deviation 
and predicted free energy of binding values 
indicated an excellent performance of both 
programs in predicting the crystallographic 
binding pose for both hMD-2 and mMD-2 
proteins (Table 1). 
LABC and LABCΔAra were predicted to bind 
both MD-2 homologues with binding poses that 
agreed with the crystallographic binding poses 
for E. coli lipid A (superimposition with E. coli 
lipid A in Figs. 8 and 9). Docking poses 
consisted of four fatty acid chains deeply 
immersed into the hydrophobic pocket of MD-2, 
establishing van der Waals and CH-π 
interactions with the side chains of most of the 
lipophilic residues of the MD-2 pocket, mainly 
consisting of aliphatic Leu, Ile and Val residues, 
aromatic Phe (numbering 76, 104, 119, 121, 126, 
147, and 151), and Tyr (numbering 102, and 
131) residues. All docked poses were found to 
participate in hydrophobic interactions with most 
of these residues. Higher efficiency in 
establishing lipophilic interactions can be 
deduced given the length of these four fatty acid 
chains. The fifth chain is placed into the groove 
or channel defined by Phe126, Leu87, Val82 and 
Arg90. This channel has been identified in the X-
ray structures of the complex of TLR4/MD-2 
with E. coli lipid A (18) as the allocation site for 
one lipid chain, allowing to complete the 
hydrophobic interface required for dimerization 
with the second TLR4/MD-2/ligand partner 
(referred to here as TLR4*/MD-2*). This 
precludes formation of the activated TLR4/MD-
2/ligand multimer. Also Phe126 has been 
proposed as a switch controlling the 
agonist/antagonist conformation of MD-2, since 
Phe126 mutation prevents dimerization and 
abolishes downstream signaling (18,53).  
Therefore, the model predicts that higher 
length of the five fatty acid chains compared to 
E. coli lipid A places the fifth chain outside the 
MD-2 pocket, thus building the dimerization 
interface in the Phe126, Leu87, Val82 and Arg90 
groove, analogously to the sixth FA of E. coli 
lipid A, while the other four chains remain inside 
the MD-2 pocket, providing stabilizing 
interactions.   
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Further, the disaccharide scaffolds of LABC 
and LABCΔAra, together with the phosphate 
groups, are predicted to be in the outer region 
and to establish electrostatic interactions with the 
polar residues which define the rim of the MD-2 
pocket (Fig. 10) The higher predicted affinity for 
LPSBC could be explained in terms of additional 
anchorage points arising from the L-Ara4N 
residues. In particular, these L-Ara4N molecules 
can establish additional interactions with MD-2. 
The hydroxyl (OH) group from Tyr102 
establishes bridged H-bonding with the OH at 
position 2 of L-Ara4N and the OH from the acyl 
chain (Fig. 10), while OH at position 3 from the 
same L-Ara4N establishes a hydrogen bond with 
the Ser118 OH group. In the case of L-Ara4N 2, 
the OH group from one of the acyl chains 
establishes a hydrogen bond with Lys122 CO 
group, whereas OH-3 and ammonium groups, 
although out of the H-bond distance range (4.5 
Å), are well oriented towards carbonyl groups 
from Lys122 and Gly123, may be enabling a 
putative H-bond networking at this site. These 
interactions could also be identified in the 
complex with the mMD-2 (data not shown). This 
predicted binding mode of LABC could thus 
explain the unexpected significant level of 
activation in the biological assays. The lack of 
some lipophilic interactions arising from the 
absent sixth fatty acid chain, in comparison to E. 
coli lipid A, could also be counterbalanced by 
these extra polar interactions from the L-Ara4N 
residues.  
Molecular model of the hTLR4/MD-2 dimer 
in complex with LPSBC–To develop a structural 
model for the TLR4/MD-2 dimer in complex 
with LPSBC we first docked the inner core 
oligosaccharide moiety of LPSBC (Fig. 1) on 
hTLR4, using as a guide the region where E. coli 
LPS inner core binds. The best binding pose was 
selected (theoretical binding free energy of -2.8 
kcal mol
-1
, by AutoDock Vina), taking also into 
account a proper orientation for the building of 
the full complex. The docked pose, 
superimposed with E. coli LPS core from PDB 
3fxi, is shown in Fig. 11. The hTLR4/core 
complex was then assembled to the MD-2/LABC 
complex (best result from AutoDock Vina 
calculations), leading to a full hTLR4/MD-
2/LPSBC complex. The receptor dimer was built 
using PDB 3fxi as a template. The full 3D 
structure of the dimer complex (Fig. 12) was 
subjected to MDS, which did not show 
meaningful differences with the docked 
complexes (data not shown). The 3D model of 
the full complex supports the key interactions for 
the molecular recognition of LPSBC that were 
described above and also confirms that the L-
Ara4N residues (including the one present in the 
LPS core region, Fig. 1) play a fundamental role 
in the complex formation, as they participate in 
H-bonding at the dimerization interfaces (Fig. 
13). First, both ammonium groups from L-Ara4N 
2 and 3 (Fig. 13) (this latter is attached to a D-
glycero-D-talo-2-octulosonic acid in the core 
moiety, Fig. 1) establish hydrogen bonds with 
the TLR4 Arg264 and Asp294 carboxylate 
groups. Second, the ammonium group of L-
Ara4N 1 is close to the Asp395 carboxylate and 
the Ser416 OH group, which belong to the 
opposite TLR4*. Third, the OH-3 from L-Ara4N 
1 establishes a H bond with Ser 415 CO group of 
TLR4* (Fig. 13). The 3D models from docking 
could suggest higher activation for LPSBC vs 
LPSBCΔAra arising from the extra anchorage 
points from arabinoses. This agrees with the 
higher endotoxic potential of LPSBC in the 
biological assays. Based on this TLR4/MD-
2/LPSBC model, we have built a new model with 
the following four mutations: D294A, R322A, 
S415A*, and S416A*. These mutations involve 
the main residues establishing interactions with 
the ammonium groups from the three Ara4N 
residues, and the OH group from terminal 
glucose (Fig. 13): (i) D294 side chain establishes 
polar interactions reinforced by hydrogen bonds 
with the ammonium group from Ara4N-3, and is 
in the proximity of the ammonium group from 
Ara4N-2, so this residue can be considered as a 
main anchorage point for TLR4/MD-2/LPSBC; 
Asp294 has been mutated to Ala to abolish this 
interaction; (ii) S415* and S416* are placed in 
the partner TLR4* and provide an anchorage 
point for ammonium group from Ara4N-1 
through polar interactions with the side chain of 
S415* and the backbone CO groups; both Ser 
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residues have been mutated to Ala; (iii) although 
not directly contacting with any of the Ara4N 
moieties, R322 side chain establishes a hydrogen 
bond with the OH group at position 3 from the 
terminal glucose, and we mutated it to compare 
its contribution to the global energy of the 
system; this interaction is absent in the complex 
of TLR4/MD2 with E. coli LPS (PDB-ID 3fxi) 
and could be considered as a distinctive 
interaction for LPSBC core. MDS and energy 
calculations of both systems (TLR4/MD-
2/LPSBC and mutant TLR4/MD-2/LPSBC) have 
shown an important difference in the global 
energy: the wild type complex (TLR4/MD-
2/LPSBC model) is around 32 kcal mol
-1
 more 
stable than the mutant counterpart, mainly due to 
the coulombic term, pointing to the presence of 
important polar interactions (Table 2). Analysis 
of the contributions of each residue to the ligand 
binding energy reveals that this energy 
difference is mainly due to the lack of the 
interactions involving the mutated residues: (i) 
interaction with D294 is the highest interaction 
in the TLR4/MD-2/LPSBC system (around 22 
kcal mol
-1
) and is absent in the mutant; (ii) also 
the interaction with R322 is missing, being one 
of the main interactions in the TLR4/MD-
2/LPSBC system (around 9.6 kcal mol
-1
); (iii) the 
lower coulombic contribution to the interaction 
energy in the mutant TLR4/MD-2/LPSBC 
complex is due to the absence of the interaction 
between the S415* side chain and the 
ammonium group. These results give reasonable 
evidences that the Ara4N ammonium groups 
provide additional anchorage interactions 
accounting for the final stability of the 
TLR4/MD-2/LPSBC complex. Abolishing these 
interactions leads to a less stable complex, 
suggesting they are crucial for the binding. 
   
DISCUSSION 
Lipid A is a major determinant of cytokine 
induction in host immune cells (11-19,54). 
Generally, the highest immunostimulatory 
activity of lipid A correlates with its hexa-
acylation pattern (11-19,54), since the sixth acyl 
chain protrudes from the MD-2 binding pocket 
bridging TLR4/MD-2 complex dimerization. On 
the contrary, underacylated lipid A molecules are 
not (or poorly) sensed by human TLR4/MD-2 
being potentially accommodated within the MD-
2 pocket. Here, we demonstrate a role for L-
Ara4N residues in lipid A that explains why the 
B. cenocepacia LPS (naturally consisting of a 
mixture of penta- and tetra-acylated forms) acts 
as a strong TLR4/MD-2 agonist. Our results 
agree with a recent report by Hollaus et al. (36), 
demonstrating that a synthetic Burkholderia lipid 
A substituted with L-Ara4N exclusively at the 
anomeric phosphate acts as a potent human 
TLR4/MD-2 agonist. 
Our in vitro and in vivo results explain and 
expand the above conclusions and show that B. 
cenocepacia penta-acylated lipid A (both LABC 
and LABCΔAra) elicits an inflammatory response 
activating the TLR4/MD-2 complex, suggesting 
that the model of the receptor complex activation 
should also include other structural components. 
Further, molecular modeling experiments 
indicated that the increased length of the two 
amide-linked acyl chains of the B. cenocepacia 
lipid A moiety (3-(R)-hydroxyhexadecanoic acid 
C16:0 (3-OH) vs 3-(R)-hydroxytetradecanoic 
acid C14:0 (3-OH) from the E. coli lipid A) 
compensates the lack of one fatty acid chain 
filling the hydrophobic binding pocket of MD-2 
protein, allowing the placement into the channel 
of the fifth acyl chain responsible for TLR4 
dimerization. The replacement in E. coli lipid A 
of the secondary dodecanoic acid C12:0 with a 
hexadecanoic acid C16:0 results in a weaker LPS 
agonist (55). However, our data indicate not only 
the increased length of the acyl chain but also its 
position is important for agonist activity.  
Further, our mutagenesis studies using two B. 
cenocepacia lipid A forms, LABC and LABCΔAra, 
uncovered differential responsiveness on 
transfected HEK293 cells indicating an 
important role also for the L-AraN residues into 
the TLR4/LABC binding process. Particularly, the 
significantly different immunostimulatory 
activity of LABC compared to LABCΔAra (Fig. 7), 
observed in presence of the human MD-2  
K122E mutation, might be related to the 
occurrence on LABC of the L-Ara4N residues, 
which could mask the negatively charged 
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phosphate groups and then reduce the repulsive 
forces introduced with the K122E mutation. In 
contrast, the absence of L-Ara4N in LABCΔAra 
might explain its increased agonistic activity 
when tested on HEK293 cells transfected with 
mTLR4/hMD-2 K122E, since the repulsive 
forces introduced might facilitate the orientation 
toward the Cys95/Cys105 loop (52-53). 
Therefore, it is reasonable to assume that the L-
Ara4N-modification with its positively charged 
ammonium group could favor the electrostatic 
interactions allowing receptor/lipid A binding. 
Intriguingly, recent work by Maeshima et al. 
(56) revealed several key charged amino acid 
residues in TLR4 and MD-2 mediating host-
specific responses to the glucosamine-modified 
penta-acylated lipid A from B. pertussis and its 
unmodified counterpart by human and mouse 
TLR4/MD-2 complexes. This further 
underscores the importance of positively charged 
residues decorating penta-acylated lipid A and 
interacting with human TLR-4/MD-2 charged 
amino acid residues to promote complex 
activation (56).   
Our molecular modeling experiments further 
supported the notion that L-Ara4N residues 
provide additional polar interactions affecting the 
LABC binding to the TLR4/MD-2 and contribute 
to anchoring the lipid A into the receptor 
complex. The network of hydrogen bonds and 
polar interactions contributing to anchoring the 
lipid A into the TLR4/MD-2 involves not only 
the sugar residues from the core oligosaccharide 
(for example, hydrogen bonds involving Arg322, 
Fig. 13), but also the three L-Ara4N residues and 
the partner TLR4*. As stated above, mutagenesis 
studies demonstrate that several Lys residues 
involved in LPS binding play indispensable roles 
through the polar interactions with the phosphate 
groups (56-59). In our dimer model, Lys122 is 
involved in binding the lipid A moiety of the 
LPSBC through polar interactions with the core; 
as for V82F, it has been already mentioned its 
role in building the groove that accommodates 
the acyl chain from lipid A, completing the 
interaction surface required for dimerization. The 
replacement of Val82 by phenylalanine involves 
changes of van der Waals interactions into CH-π 
interactions, which may favor the binding of this 
chain, longer than the corresponding one on E. 
coli LPS.  
Thus, the structural peculiarities of B. 
cenocepacia i.e., its acylation pattern and the 
presence of the L-Ara4N residues in the lipid A 
region exert a synergistic effect in the activation 
and dimerization of the LPS receptor opening 
new insights into the comprehension of the 
molecular recognition of LPS by TLR4/MD-2.   
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FIGURE LEGENDS  
 
FIGURE 1. Structure of Burkholderia cenocepacia LPS inner core and lipid A. B. cenocepacia 
lipid A is heterogeneous, being composed of a mixture of penta- and tetra-acylated species (30,40). 
Lipid A fatty acids are two 3-(R)-hydroxthexadecanoic acids, two 3-(R)-hydroxytetradecanoic acids 
and one tetradecanoic acid (30,40). The dotted lines indicate the non-stoichiometric substitution.  
 
FIGURE 2. LPSBC activates the murine and human TLR4/MD-2 complexes. NF-κB activation 
upon stimulation of HEK293 mTLR4/mMD-2 and hTLR4/hMD-2 after 6 h with 5 ng/ml of LPSBC and 
LPSBCΔAra. Stimulation for 6 h with E. coli LPS was used as control. The data are pooled from three 
independent experiments done in triplicate. Bars indicate standard deviation; significance was 
calculated in comparison to stimulation with E. coli LPS (*P <0.05, **P <0.01, ***P <0.001). Curly 
brackets indicate significance calculated comparing LPSBC and LPSBCΔAra (*P <0.05, **P <0.01, ***P 
<0.001). 
 
FIGURE 3.  Lipid A activation of murine and human TLR4/MD2-complexes. A. NF-κB 
activation upon stimulation of HEK293 mTLR4/mMD-2 after 6 h with LABC and LABCΔAra. 
Stimulations for 6 h with E. coli LPS, hexa-acylated lipid A and lipid IVA were used as controls. The 
data are pooled from three independent experiments done in triplicate. Bars indicate standard 
deviation; significance was calculated in comparison to stimulation with hexa-acylated E. coli lipid A 
(*P <0.05, **P <0.01, ***P <0.001); curly brackets indicate significance calculated comparing LPSBC 
and LPSBCΔAra (*P <0.05, **P <0.01, ***P <0.001). B. NF-κB activation upon stimulation of  EK293 
hTLR4/hMD-2 after 6 h with LABC and LABCΔAra. Stimulations for 6 h with E. coli LPS, hexa-acylated 
lipid A and lipid IVA were used as controls. The data are pooled from three independent experiments 
done in triplicate. Bars indicate standard deviation; significance was calculated in comparison to 
stimulation with hexa-acylated E. coli lipid A (*P <0.05, **P <0.01, ***P <0.001); curly brackets 
indicate significance calculated comparing LPSBC and LPSBCΔAra (*P <0.05, **P <0.01, ***P <0.001). 
 
FIGURE 4. B. cenocepacia LPSBCΔAra effects on the E. coli LPS agonist activity. Assay on the 
potential antagonist activity of LPSBC and LPSBCΔAra on hexa-acylated E. coli LPS. NF-κB activation 
upon stimulation of HEK293 hTLR4 after 1 h with LPSBC (1, 10 and 100 ng/ml) and LPSBCΔAra (1, 10 
and 100 ng/ml) and then exposed to E. coli LPS (1 and 10 ng/ml) for 4 h. The data are pooled from 
three independent experiments done in triplicate. Bars indicate standard deviation; significance was 
calculated in comparison to stimulation with E. coli LPS (1 and 10 ng/ml) (*P <0.05, **P <0.01, ***P 
<0.001). 
 
FIGURE 5. Pro-inflammatory and endotoxic potential of LPSBC in C57Bl/6 mice. From three 
mice to five per group were challenged via intraperitoneal injection with 300 μg/mouse of LPS from 
E. coli, P. aeruginosa RP73, LPSBC and LPSBCΔAra. TNF-α levels in sera were quantified after 5 h of 
treatment. Treatment with sterile saline solution was used as control (Ctrl). The data are pooled from 
two independent experiments. Results are reported as mean±S.D. Statistical analysis was made for 
pair wise comparisons (*P <0.05, **P <0.01, ***P <0.001). 
 
FIGURE 6. B. cenocepacia LPS acylation pattern is responsible for the NF-κB activation. NF-κB 
activation upon stimulation of HEK293 hTLR4/hMD-2 after 6 h with LPSBC and LPSBCΔAra. 
Stimulation for 6 h with E. coli LPS was used as control. The same protocol was used to stimulate 
HEK293 hTLR4/hMD-2 V82F cells. The data are pooled from three independent experiments done in 
triplicate. Bars indicate standard deviation; significance was calculated in comparison to E. coli LPS 
(*P <0.05, **P <0.01, ***P <0.001). 
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FIGURE 7. Lys-122 and Lys-125 in the B. cenocepacia LPS signaling on murine and human 
TLR4/MD-2 complexes. NF-κB-luciferase reporter assay executed stimulating HEK293 
hTLR4/hMD-2, HEK293 mTLR4/mMD-2 and mTLR4/hMD-2 after 6 h with LPSBC and LPSBCΔAra. 
Stimulations for 6 h with E. coli LPS and with lipid IVA were used as controls. The same protocol was 
used to stimulate HEK293 mTLR4/mMD-2 E1222K and HEK293 mTLR4/mMD-2 E122K L125K 
cells. The data are pooled from two independent experiments done in triplicate. Bars indicate standard 
deviation; statistical analysis was calculated for pair wise comparisons (*P <0.05, **P <0.01, ***P 
<0.001). 
 
FIGURE 8. Predicted binding mode of the LPSBC core to hTLR4/MD-2. Computational model 
from docking followed by MDS. LPSBC docked to MD-2 is shown in CPK colors. Superimposed fatty 
acids chains from E. coli lipid A are shown in different colors. Some representative residues from the 
MD-2 binding site are represented with carbon atoms in green.  
 
FIGURE 9. Predicted binding mode of the LPSBC core to hTLR4/MD-2. Details of LPSBC (CPK 
colours) docked to MD-2. Superimposed fatty acids chains from E. coli lipid A are shown with carbon 
atoms in blue. 
 
FIGURE 10. Predicted binding mode of the LPSBC core to hTLR4/MD-2. Detail of some H-bond 
interactions between the LPSBC inner core and TLR4/MD-2 involving Tyr102. LPSBC is represented in 
CPK colors and MD-2 protein is represented in green. 
 
FIGURE 11. Superimposition of best dock results of LPSBC core. The docking was obtained using 
AutoDock Vina (depicted in red) and E. coli LPS core from PDB 3fxi (depicted in green). TLR4 is not 
shown for the sake of clarity. 
 
FIGURE 12. Predicted binding mode of the LPSBC core to hTLR4/MD-2. Computational model 
from docking followed by MDS. Left panel) 3D Model of the dimer of LPSBC core in complex with 
TLR4/MD-2. Right panel) Detail of the dimer of LPSBC inner core in complex with TLR4/MD-2. 
 
FIGURE 13. Predicted binding mode of the LPSBC core to hTLR4/MD-2. Details of some 
interactions between the LPSBC inner core and TLR4/MD-2 from the computational model. 
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Table 1. Theoretical free energy of binding for the docking calculations with AutoDock 
4.2 and AutoDock Vina (in bold). Energy values are in kcal mol
-1
. Root-mean-square 
deviation (RMSD) values are in Å. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 human MD-2 murine MD-2 
LABC -20.02/-25.30 -17.73/-23.60 
LABCΔAra -18.22/-18.60 -13.09/-17.20 
E. coli lipid A -24.41/-28.3 
(RMSD = 0.282/0.599) 
-24.73/-27.9 
(RMSD = 0.647/0.394) 
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Table 2. Analysis of the per residue contributions to the total ligand binding energy for both complexes TLR4/MD-2/LPSBC and the 
mutated TLR4/MD-2/LPSBC (D294A, R322A, S415A*, and S416A*). Energy calculations come from the MDS. Only the top 22 contributions 
are shown (top 20 in the case of the mutant). Residues from TLR4 are underlined. Residues from the partner TLR4 are also marked with *. 
 
WT TLR4/MD-2/LPSBC complex 
 
Mutated TLR4/MD-2/LPSBC complex 
 
Residue Coulombic vdW Desolv Apolar HBond Total Coulombic vdW Desolv Apolar HBond Total 
 
Asp294 -23.8236 -0.3210 7.0629 -0.9545 -4.0000 -22.0362 interaction not present in the mutated complex 
Arg362 -11.8934 -0.7918 0.7816 -0.4113 -2.0000 -14.3149 -12.0533 -0.6813 0.8190 -0.4471 -2.0000 -14.3627 
Phe121 0.0130 -10.1848 0.5344 -0.6027 0.0000 -10.2401 0.0197 -10.1477 0.5580 -0.6261 0.0000 -10.1961 
Lys362 -5.1955 -5.2246 1.0497 -0.4985 0.0000 -9.8689 -5.2429 -5.1940 1.0644 -0.5256 0.0000 -9.8981 
Arg322 -4.1694 -3.0209 1.4981 -0.3240 -3.5617 -9.5779 interaction not present in the mutated complex 
Ser120 -3.1530 -7.4177 2.8502 -0.6139 -1.1234 -9.4577 -3.1426 -7.4262 2.8920 -0.6447 -1.0989 -9.4204 
Ser118 -2.8535 -5.8601 1.9418 -0.4578 -1.0000 -8.2297 -2.8551 -5.8194 1.9806 -0.4812 -1.0000 -8.1751 
Phe119 -1.5159 -6.4383 0.3843 -0.3698 0.0000 -7.9398 -1.4890 -6.4515 0.3876 -0.3904 0.0000 -7.9433 
Ser415* -2.4352 -5.8271 1.9501 -0.4780 -0.3041 -7.0943       
Ile124 -0.1801 -6.4039 0.3739 -0.4557 0.0000 -6.6657 -0.1810 -6.3430 0.3881 -0.4727 0.0000 -6.6086 
Arg264 -1.1413 -5.5336 2.6335 -0.4594 -2.0000 -6.5008 -1.1644 -5.5411 2.6761 -0.4832 -2.0000 -6.5125 
Phe440* -0.1050 -5.6291 0.2835 -0.3229 0.0000 -5.7735 -0.0997 -5.6015 0.2967 -0.3374 0.0000 -5.7419 
Ile117 -0.2575 -5.3521 0.2913 -0.3661 0.0000 -5.6844 -0.2411 -5.3782 0.3048 -0.3803 0.0000 -5.6949 
Phe126 0.0689 -5.4883 0.4065 -0.4173 0.0000 -5.4302 0.0642 -5.5509 0.4229 -0.4337 0.0000 -5.4975 
Tyr269 -0.5477 -5.1443 1.3327 -0.3411 -0.3869 -5.0874 -0.5489 -5.4268 1.4007 -0.3883 -0.2386 -5.2018 
Ser415*       -0.4672 -4.9035 0.9431 -0.3809 -0.2240 -5.0324 
Leu61 0.0348 -4.6148 0.4221 -0.3884 0.0000 -4.5462 0.0351 -4.5972 0.4323 -0.4004 0.0000 -4.5303 
Arg90 -0.2914 -5.6957 2.2470 -0.3640 0.0000 -4.1041 -0.2934 -5.6883 2.2559 -0.3797 0.0000 -4.1056 
Ile52 0.0059 -3.9534 0.1916 -0.2931 0.0000 -4.0491 0.0059 -3.9438 0.2011 -0.3046 0.0000 -4.0414 
Ile80 0.0264 -3.6513 0.2132 -0.2699 0.0000 -3.6815 0.0263 -3.6317 0.2209 -0.2775 0.0000 -3.6619 
Phe151 0.0061 -3.4402 0.2277 -0.2298 0.0000 -3.4362 0.0060 -3.4279 0.2354 -0.2380 0.0000 -3.4245 
Arg122 -0.9785 -3.6363 1.4626 -0.2523 0.0000 -3.4046 -0.9571 -3.6698 1.4845 -0.2670 0.0000 -3.4095 
Tyr131 0.0104 -3.4712 0.4052 -0.2474 0.0000 -3.3029 0.0099 -3.4703 0.4135 -0.2570 0.0000 -3.3039 
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Figure 1 
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Figure 2 
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Figure 3A 
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Figure 3B 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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Figure 11 
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Figure 12 
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Figure 13 
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